Monitor the MAPLE-HCM late-breaking data at the congress (May 11) for potential differentiation vs. metoprolol, but this is a scientific meeting update with no immediate stock-moving catalyst. Watch for future regulatory decisions in additional geographies or label expansions.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $60.69entry
- T+1 · 7mo ago −1.83%α −1.82% · $59.58
- T+5 · 7mo ago +27.02%α +25.33% · $77.09
- T+20 · 6mo ago +27.12%α +21.67% · $77.15
- T+60 · 4mo ago +34.98%α +30.99% · $81.92
Price Chart
How similar events traded
Executive Summary
Cytokinetics announced nine presentations at the ESC Heart Failure 2026 Congress, including a late-breaking oral presentation on the MAPLE-HCM study comparing aficamten to metoprolol in obstructive HCM. The presentations highlight ongoing clinical data generation for MYQORZO (aficamten), which is already approved in the U.S., EU, and China for oHCM, but no new regulatory or commercial catalysts were disclosed.
Key Facts
- Nine presentations at ESC Heart Failure 2026 Congress (May 9–12, 2026) including a late-breaking oral presentation on MAPLE-HCM study comparing aficamten vs. metoprolol in oHCM.
- MYQORZO (aficamten) is approved in U.S., EU, and China for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Aficamten is under investigation in Phase 3 trials for non-obstructive HCM (ACACIA-HCM) and pediatric oHCM (CEDAR-HCM).
- No new regulatory decisions, financial results, or commercial updates were provided in this press release.
Financial Impact
No financial figures disclosed; scientific conference presentations are routine and do not directly impact revenue or earnings.
Risk Factors
- Competition from existing oHCM therapies (e.g., mavacamten) could limit MYQORZO market share.
- Clinical trial results for nHCM or pediatric indications may not meet endpoints.
- Regulatory setbacks in new indications or geographies could impact revenue expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282479 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers